Status:
TERMINATED
Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
Lead Sponsor:
Swedish Medical Center
Collaborating Sponsors:
Sanofi-Synthelabo
Conditions:
Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.
Eligibility Criteria
Inclusion
- Previously untreated extensive small cell lung cancer
- No prior chemotherapy
- No prior radiotherapy except for the treatment of brain metastases
Exclusion
- Prior treatment for extensive stage small cell lung cancer
- Known hypersensitivity to any of the components of oxaliplatin or CPT-11
- Greater than grade 2 peripheral neuropathy
- Known HIV or Hepatitis B or C (active, previously treated or both)
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00316433
Start Date
February 1 2005
End Date
January 1 2007
Last Update
April 5 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Swedish Medical Center Cancer Institute
Seattle, Washington, United States, 98104